Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2021 April;40(2) > International Angiology 2021 April;40(2):170-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

ORIGINAL ARTICLE  MISCELLANEOUS Freefree

International Angiology 2021 April;40(2):170-5

DOI: 10.23736/S0392-9590.21.04556-9

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Reasoned therapeutic protocol in outpatients with COVID-19

Claudio ALLEGRA 1, Giacomo FAILLA 2 , Luca COSTANZO 2, Ferdinando MANNELLO 3, Francesco MONTELLA 4, Pier L. ANTIGNANI 5

1 Department of Angiology, Union Internationale de Phlebologie (UIP), S.Giovanni Hospital, Rome, Italy; 2 Unit of Angiology, Department of Cardiovascular Disease, San Marco Hospital, Rodolico, S. Marco University Hospital, University of Catania, Catania, Italy; 3 Unit of Clinical Biochemistry, Section of Biochemistry and Biotechnology, Department of Biomolecular Sciences, Carlo Bo University of Urbino, Urbino, Pesaro-Urbino, Italy; 4 Department of Internal Medicine, San Giovanni-Addolorata Hospital, Rome, Italy; 5 Vascular Center, Nuova Villa Claudia, Rome, Italy



BACKGROUND: Seventy percent of patients affected by SARS-COV-2 disease are asymptomatic or with symptoms that not required Hospitalization. A prodromal period lasting about 5 days can be identified. In this phase a patient with a positive swab for viral RNA may or may not evolve towards the phase of symptomatic disease.
METHODS: In this paper we reviewed the literature related to COVID-19 therapy we propose a reasoned treatment protocols in outpatients according to the age and the comorbidity.
RESULTS: The aim of this study was to reduce the impact of the virus by reducing its ability to attack cells and the inflammatory burden and the prothrombotic effects proposing two therapeutic schemes of proven efficacy according to the age of the patients and the comorbidities.
CONCLUSIONS: We aimed to reduce worsening of clinical status and hospitalization while protecting patients at home.


KEY WORDS: COVID-19; Therapeutics; Blood coagulation disorders; Heparin, low-molecular-weight; Thrombosis

inizio pagina